Alibaba Health's top line and bottom line for FY 2021 were below expectations, and a key contributing factor was the revenue growth slowdown in 2H FY 2021.
The strong growth in lower-margin prescription drugs sales was another reason for Alibaba Health's lower-than-expected FY 2021 earnings, and this could continue to be a drag on its future profitability.
Online medical & healthcare services is showing signs of being a significant growth driver for Alibaba Health in the long term, with its new app breaking the one million MAU mark.
Alibaba Health trades at 8.9 times consensus forward next twelve months'
Mark Mark OP : Summary
Alibaba Health's top line and bottom line for FY 2021 were below expectations, and a key contributing factor was the revenue growth slowdown in 2H FY 2021.
The strong growth in lower-margin prescription drugs sales was another reason for Alibaba Health's lower-than-expected FY 2021 earnings, and this could continue to be a drag on its future profitability.
Online medical & healthcare services is showing signs of being a significant growth driver for Alibaba Health in the long term, with its new app breaking the one million MAU mark.
Alibaba Health trades at 8.9 times consensus forward next twelve months'